Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0306343 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Zeyuan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Control Science and Engineering, Dalian University of Technology, Dalian, Liaoning, China. Hauptthemen laut MEDLINE: DNA Copy Number Variations, Neoplasms, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “1+X’’ Program Cross-Disciplinary Innovation Project.
Abstract (Originalsprache)
Due to the heterogeneity of cancer, precision medicine has been a major challenge for cancer treatment. Determining medication regimens based on patient genotypes has become a research hotspot in cancer genomics. In this study, we aim to identify key biomarkers for targeted therapies based on single nucleotide variants (SNVs) and copy number variants (CNVs) of genes. The experiment is carried out on 7 cancers on the Encyclopedia of Cancer Cell Lines (CCLE) dataset. Considering the high mutability of driver genes which result in abundant mutated samples, the effect of data sparsity can be eliminated to a large extent. Therefore, we focus on discovering the relationship between driver mutation patterns and three measures of drug response, namely area under the curve (AUC), half maximal effective concentration (EC50), and log2-fold change (LFC). First, multiple statistical methods are applied to assess the significance of difference in drug response between sample groups. Next, for each driver gene, we analyze the extent to which its mutations can affect drug response. Based on the results of multiple hypothesis tests and correlation analyses, our main findings include the validation of several known drug response biomarkers such as BRAF , NRAS , MAP2K1 , MAP2K2 , and CDKN2A , as well as genes with huge potential to infer drug responses. It is worth emphasizing that we identify a list of genes including SALL4 , B2M , BAP1 , CCDC6 , ERBB4 , FOXA1 , GRIN2A , and PTPRT , whose impact on drug response spans multiple cancers and should be prioritized as key biomarkers for targeted therapies. Furthermore, based on the statistical p-values and correlation coefficients, we construct gene-drug sensitivity maps for cancer drug recommendation. In this work, we show that driver mutation patterns could be used to tailor therapeutics for precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Control Science and Engineering, Dalian University of Technology, Dalian, Liaoning, China.
- Department of Breast Surgery, Institute of Breast Disease, Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
ORCID-Profile: Zeyuan Wang, Jia Wang
Förderung
- “1+X’’ Program Cross-Disciplinary Innovation Project
Zitieren
APA
Wang, Z., Gu, H., Qin, P., & Wang, J. (2024). Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers. PLOS ONE. https://doi.org/10.1371/journal.pone.0306343
Vancouver
Wang Z, Gu H, Qin P, Wang J. Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers. PLOS ONE. 2024. doi:10.1371/journal.pone.0306343
BibTeX
@article{Wang2024,
author = {Wang, Zeyuan and Gu, Hong and Qin, Pan and Wang, Jia},
title = {Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0306343}
}
EUVIMED